Open AccessDual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves oocyte yield in normal responders on GnRH-antagonist cycles
Author(s) -
Soha Albeitawi,
Ehab Abu Marar,
Firas Al Reshoud,
Jehan Hamadneh,
Rami Hamza,
Ghassan Alhasan,
Haya Omeish,
Paola Viganò
Publication year - 2022
Publication title -
jbra
Language(s) - English
Resource type - Journals
eISSN - 1518-0557
pISSN - 1517-5693
DOI - 10.5935/1518-0557.20210039
Subject(s) - oocyte , human chorionic gonadotropin , agonist , in vitro fertilisation , human fertilization , gonadotropin , andrology , luteinizing hormone , gonadotropin releasing hormone antagonist , ovarian hyperstimulation syndrome , gonadotropin releasing hormone , medicine , endocrinology , pregnancy , hormone , biology , receptor , embryo , anatomy , microbiology and biotechnology , genetics
During in vitro fertilization (IVF) cycles, final oocyte maturation is usually triggered by human Chorionic Gonadotropin (hCG) for its known effect in mimicking Luteinizing Hormone (LH) surge; however, with the widespread use of the 'antagonist protocol', Gonadotropin Releasing Hormone agonist (GnRHa) is being more commonly employed as a trigger in order to minimize or eliminate the risk of ovarian hyper-stimulation syndrome (OHSS). Many studies proved its efficacy in inducing oocyte maturation and its safety in preventing OHSS in high-risk groups. Moreover, some studies showed that GnRHa trigger may improve oocyte yield. This study aimed to further explore any beneficial effect of adding GnRHa to hCG (dual trigger) on oocyte yield and fertilization rate in normal responder women.